ESMO-Advanced-Courses-Precision-Medicine-2022-1000x250-october

Start date: 09 Oct 2022
End date: 10 Oct 2022
Location: Singapore, Republic of Singapore

Learning objectives

To acknowledge that an increasing number of therapeutics that require biomarkers testing are available for clinical use or are in an advanced phase of clinical development
To understand how different technologies can be used for biomarker testing depending on the nature of the biomarker and the availability of biological samples
To draw attention to the increasing use of large panels for comprehensive genomic profiling raises issues on data interpretation that require a multidisciplinary approach
To obtain in-depth understanding of how monitoring the molecular evolution of the disease might allow the identification of resistance mechanisms and the development of more effective therapeutic strategies
To understand that the identification of germline variants requires the activation of genetic counselling programs for patients and their families

Accreditation

The programme of this event has been accredited with 9 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.

Co-Chairs

Kohei Shitara, Japan
Albrecht Stenzinger, Germany

Learning objectives

Accreditation

Co-Chairs

Supported by